

ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND RELATED METHODS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Nos. 62/613,545, filed January 4, 2018; 62/613,564, filed January 4, 2018; 62/646,788, filed March 22, 2018; 62/713,797, filed August 2, 2018; and 62/713,804, filed August 2, 2018, each of which is hereby incorporated by reference in its entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on ~~Month-XX~~February 28, 2019~~XX~~, is named [41904WO CRF sequencelisting.txt](#)~~XXXXXXUS_sequencelisting.txt~~, and is [382,993](#)~~X,XXX,XXX~~ bytes in size.

BACKGROUND

[0003] Blood coagulation involves a complex set of processes that result in blood clotting. Tissue factor (TF) plays an important role in these coagulation processes. TF is a cell surface receptor for the serine protease factor VIIa (FVIIa). The TF/FVIIa complex catalyzes conversion of the inactive protease factor X (FX) into the active protease factor Xa (FXa). FXa and its co-factor FVa form the prothrombinase complex, which generates thrombin from prothrombin. Thrombin converts soluble fibrinogen into insoluble strands of fibrin and catalyzes many other coagulation-related processes.

[0004] TF is over-expressed on multiple types of solid tumors. In cancer, TF/FVIIa signaling can support angiogenesis, tumor progression, and metastasis. Increased TF expression can also induce inflammation and/or angiogenesis in many other diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy.

SUMMARY

[0005] Provided herein are antibodies that specifically bind human Tissue Factor (TF), anti-TF antibody-drug conjugates, and related methods.

[0005a] In one aspect, provided herein is an isolated antibody which binds to human Tissue Factor (TF), wherein the isolated antibody comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain complementarity determining regions (CDRs) (VL-CDR1, VL-CDR2, and VL-CDR3).

wherein the VH-CDR1, VH-CDR2, and VH-CDR3 are from a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO:836, and wherein the VL-CDR1, VL-CDR2, and VL-CDR3 are from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO:837.

[0005b] In one aspect, provided herein is an isolated antibody which binds to human TF and comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain CDRs (VL-CDR1, VL-CDR2, and VL-CDR3), wherein: the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 890, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 891, and the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 892, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 893, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 894, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:895, and wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are defined according to the Kabat numbering system.

[0006] In one ~~aspect~~example, provided herein is an isolated human antibody which binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa.

[0007] In some ~~embodiment~~examples, (1) the isolated antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference

antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0008] In some [embodiment examples](#), (1) the isolated antibody inhibits human thrombin generation to a lesser extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0009] In some [embodiment examples](#), (1) the isolated antibody allows human thrombin generation to a greater extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0010] In some [embodiment examples](#), (1) the isolated antibody inhibits human thrombin generation by a lesser amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0011] In some [embodimentexamples](#), (1) the isolated antibody allows human thrombin generation by a greater amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0012] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.

[0013] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.

[0014] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.

[0015] In some [embodimentexamples](#), the isolated antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[0016] In some [embodimentexamples](#), the isolated antibody inhibits human thrombin generation to a lesser extent as determined by thrombin generation assay (TGA) compared to a reference

antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[0017] In some [embodimentexamples](#), the isolated antibody allows human thrombin generation to a greater extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[0018] In some [embodimentexamples](#), the isolated antibody inhibits human thrombin generation by a lesser amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[0019] In some [embodimentexamples](#), the isolated antibody allows human thrombin generation by a greater amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[0020] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA). In some [embodimentexamples](#), the antibody does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control. In some [embodimentexamples](#), the antibody does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control. In some [embodimentexamples](#), the antibody does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control. In some [embodimentexamples](#), the antibody allows human thrombin generation as determined by thrombin generation assay (TGA). In some [embodimentexamples](#), the antibody maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control. In some [embodimentexamples](#), the antibody maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control. In some [embodimentexamples](#), the antibody preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.

[0021] In some [embodimentexamples](#), the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX. In some [embodimentexamples](#), the antibody does not interfere with the ability of TF:FVIIa to convert FX into FXa.

[0022] In some [embodimentexamples](#), the antibody does not compete for binding to human TF with human FVIIa.

[0023] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), allows human thrombin generation as determined by thrombin generation assay (TGA), binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[0024] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[0025] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[0026] In some [embodimentexamples](#), the antibody inhibits FVIIa-dependent TF signaling.

[0027] In some [embodimentexamples](#), the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the

median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N.

[0028] In some [embodimentexamples](#), the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.

[0029] In some [embodimentexamples](#), the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0030] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0031] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0032] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence

shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0033] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0034] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0035] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0036] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0037] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID

NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0038] In some [embodiment examples](#), the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0039] In some [embodiment examples](#), the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158

of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some **embodiment**[examples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.

[0040] In some **embodiment**[examples](#), the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino

acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some **embodiment** examples, the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; the mutation at amino acid residue 68 of the sequence shown in SEQ ID

NO:810 is K68N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0041] In some [embodimentexamples](#), the antibody binds to cynomolgus TF. In some [embodimentexamples](#), the antibody binds to mouse TF. In some [embodimentexamples](#), the antibody binds to rabbit TF. In some [embodimentexamples](#), the antibody binds to pig TF.

[0042] In some [embodimentexamples](#), the antibody reduces lesion size in a swine choroidal neovascularization (CNV) model.

[0043] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); and (b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0044] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); and (b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0045] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell

staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0046] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0047] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) binds to cynomolgus TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0048] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); (b) binds to cynomolgus TF; (c) the

binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some ~~embodiment~~examples, the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[0049] In some ~~embodiment~~examples, the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) allows human thrombin generation as determined by thrombin generation assay (TGA); (c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (e) does not compete for binding to human TF with FVIIa; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus TF; (h) binds to mouse TF; and (i) binds to rabbit TF.

[0050] In some ~~embodiment~~examples, the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by thrombin generation assay (TGA); (d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (g) does not compete for binding to human TF with FVIIa; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus TF; (j) binds to mouse TF; and (k) binds to rabbit TF.

[0051] In some ~~embodiment~~examples, the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak)

compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; and (o) binds to rabbit TF.

[0052] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) allows human thrombin generation as determined by thrombin generation assay (TGA); (c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (e) does not compete for binding to human TF with FVIIa; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus TF; (h) binds to mouse TF; (i) binds to rabbit TF; (j) binds to pig TF; and (k) reduces lesion size in a swine choroidal neovascularization (CNV) model.

[0053] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by thrombin generation assay (TGA); (d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (g) does not compete for binding to human TF with FVIIa; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus TF; (j) binds to mouse TF; (k) binds to rabbit TF; (l) binds to pig TF; and (m) reduces lesion size in a swine choroidal neovascularization (CNV) model.

[0054] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on

a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to pig TF; and (q) reduces lesion size in a swine choroidal neovascularization (CNV) model.

[0055] In some ~~embodiment~~[examples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to pig TF; (q) reduces lesion size in a swine choroidal neovascularization (CNV) model; (r) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the

isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (s) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (t) the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (u) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (v) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (w) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (x) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of

the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (y) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (z) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (aa) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (bb) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and(cc) wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0056] In some [embodiment examples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to pig TF; (q) reduces lesion size in a swine choroidal neovascularization (CNV) model; (r) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation K149N of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (s) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation K68N of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (t) the binding between the isolated antibody and a variant TF extracellular domain comprising mutations N171H and T197K of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (u) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence

shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (v) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (w) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (x) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (y) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (z) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (aa) the binding between the isolated antibody

and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; (bb) the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and (cc) wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0057] In some **embodiment**[examples](#), the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0058] In some **embodiment**[examples](#), the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0059] In some **embodiment**[examples](#), the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0060] In some [embodimentexamples](#), the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0061] In some [embodimentexamples](#), the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0062] In some [embodimentexamples](#), the antibody binds to the same human TF epitope bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0063] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some [embodimentexamples](#), the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

[0064] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A5-T, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0065] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0066] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.

[0067] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:113 and a V_L sequence of SEQ ID NO:114. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:151 and a V_L sequence of SEQ ID NO:152. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:189 and a V_L sequence of SEQ ID NO:190. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:836 and a V_L sequence of SEQ ID NO:837. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:227 and a V_L sequence of SEQ ID NO:228. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:265 and a V_L sequence of SEQ ID NO:266. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:303 and a V_L sequence of SEQ ID NO:304. In some [embodimentexamples](#), the antibody comprises a V_H

sequence of SEQ ID NO:455 and a V_L sequence of SEQ ID NO:456. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:493 and a V_L sequence of SEQ ID NO:494. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:531 and a V_L sequence of SEQ ID NO:532. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:569 and a V_L sequence of SEQ ID NO:570. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:607 and a V_L sequence of SEQ ID NO:608. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:645 and a V_L sequence of SEQ ID NO:646. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:683 and a V_L sequence of SEQ ID NO:684. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:721 and a V_L sequence of SEQ ID NO:722.

[0068] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.

[0069] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:763 and a V_L sequence of SEQ ID NO:764. In some [embodimentexamples](#), the antibody comprises a V_H

sequence of SEQ ID NO:868 and a V_L sequence of SEQ ID NO:869. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:870 and a V_L sequence of SEQ ID NO:871. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:769 and a V_L sequence of SEQ ID NO:770.

[0070] In some [embodimentexamples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0071] In some [embodimentexamples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0072] In some [embodimentexamples](#), the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0073] In some [embodimentexamples](#), the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0074] In some [embodimentexamples](#), the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0075] In some [embodimentexamples](#), the antibody consists of: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0076] In another [aspectexample](#), provided herein is an isolated antibody comprising all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the

antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0077] In some [embodimentexamples](#), the antibody is human, humanized, or chimeric.

[0078] In some [embodimentexamples](#), the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

[0079] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0080] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.

[0081] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0082] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain

CDRs from the antibody designated 43D. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.

[0083] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:113 and a V_L sequence of SEQ ID NO:114. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:151 and a V_L sequence of SEQ ID NO:152. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:189 and a V_L sequence of SEQ ID NO:190. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:836 and a V_L sequence of SEQ ID NO:837. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:227 and a V_L sequence of SEQ ID NO:228. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:265 and a V_L sequence of SEQ ID NO:266. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:303 and a V_L sequence of SEQ ID NO:304. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:455 and a V_L sequence of SEQ ID NO:456. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:493 and a V_L sequence of SEQ ID NO:494. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:531 and a V_L sequence of SEQ ID NO:532. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:569 and a V_L sequence of SEQ ID NO:570. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:607 and a V_L sequence of SEQ ID NO:608. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:645 and a V_L sequence of SEQ ID NO:646. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:683 and a V_L sequence of SEQ ID NO:684. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:721 and a V_L sequence of SEQ ID NO:722.

[0084] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the

sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.

In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some

[embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.

[0085] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:763 and a V_L sequence of SEQ ID NO:764. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:868 and a V_L sequence of SEQ ID NO:869. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:870 and a V_L sequence of SEQ ID NO:871. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:769 and a V_L sequence of SEQ ID NO:770.

[0086] In some [embodimentexamples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0087] In some [embodimentexamples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0088] In some [embodimentexamples](#), the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the

antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0089] In some [embodiment examples](#), the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0090] In some [embodiment examples](#), the antibody consists: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[0091] In some [embodiment examples](#), the antibody consists: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[0092] In another [aspect example](#), provided herein is an isolated antibody that competes for binding to human TF with: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

[0093] In some [embodiment examples](#), the antibody is human, humanized, or chimeric.

[0094] In some [embodiment examples](#), the antibody inhibits FVIIa-dependent TF signaling.

[0095] In some [embodiment examples](#), the antibody binds to cynomolgus TF.

[0096] In some [embodiment examples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0097] In some [embodiment examples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and

the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0098] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[0099] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[00100] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[00101] In some [embodimentexamples](#), the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the isolated antibody and a human TF extracellular domain with amino acid residues

78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

[00102] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E. In some [embodimentexamples](#), the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

[00103] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1F. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1G. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29D. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29E. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 39A. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 54E.

[00104] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:37 and a V_L sequence of SEQ ID NO:38. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:75 and a V_L sequence of SEQ ID NO:76. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:341 and a V_L sequence of SEQ ID NO:342. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:379 and a V_L sequence of SEQ ID NO:380. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:417 and a V_L sequence of SEQ ID NO:418. In some [embodimentexamples](#),

the antibody comprises a V_H sequence of SEQ ID NO:759 and a V_L sequence of SEQ ID NO:760.

[00105] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778.

In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790. In some

[embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796. In some

[embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.

[00106] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:761 and a V_L sequence of SEQ ID NO:762. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:765 and a V_L sequence of SEQ ID NO:766. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:767 and a V_L sequence of SEQ ID NO:768. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:771 and a V_L sequence of SEQ ID NO:772.

[00107] In some [embodimentexamples](#), the antibody comprises: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

[00108] In some [embodimentexamples](#), the antibody consists of: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

[00109] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778.

[00110] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.

[00111] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790.

[00112] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796.

[00113] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.

[00114] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.

[00115] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.

[00116] In another [aspectexample](#), provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.

[00117] In some [embodimentexamples](#), the antibody binds to human TF with a K_D of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM or 0.1 nM, as measured by Octet QK384 or Biacore assay.

[00118] In some [embodimentexamples](#), the antibody is a monoclonal antibody.

[00119] In some [embodimentexamples](#), the antibody is multispecific.

[00120] In some [embodimentexamples](#), the antibody is a Fab, Fab', F(ab')₂, Fv, scFv, (scFv)₂, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody.

[00121] In some [embodimentexamples](#), the antibody comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of IgG1.

[00122] In some [embodimentexamples](#), the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular

cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or decreased effector function, compared with the Fc without the one or more modifications.

[00123] In another [aspectexample](#), provided herein is an isolated antibody that competes for binding to human TF with any antibody above.

[00124] In another [aspectexample](#), provided herein is an isolated antibody that binds the human TF epitope bound by any antibody above.

[00125] In another [aspectexample](#), provided herein is an isolated polynucleotide or set of polynucleotides encoding any antibody above, a V_H thereof, a V_L thereof, a light chain thereof, a heavy chain thereof, or an antigen-binding portion thereof.

[00126] In another [aspectexample](#), provided herein is a vector or set of vectors comprising the polynucleotide or set of polynucleotides above.

[00127] In another [aspectexample](#), provided herein is a host cell comprising the polynucleotide or set of polynucleotides above or the vector or set of vectors above.

[00128] In another [aspectexample](#), provided herein is a method of producing an antibody comprising expressing the antibody with the host cell above and isolating the expressed antibody.

[00129] In another aspect, provided herein is a pharmaceutical composition comprising any antibody above and a pharmaceutically acceptable excipient.

[00130] In another [aspectexample](#), provided herein is a method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of any antibody above or the pharmaceutical composition above.

[00131] In some [embodimentexamples](#), the disease or condition is cancer. In some [embodimentexamples](#), the cancer is head and neck cancer. In some [embodimentexamples](#), the cancer is ovarian cancer. In some [embodimentexamples](#), the cancer is gastric cancer. In some [embodimentexamples](#), the cancer is esophageal cancer. In some [embodimentexamples](#), the cancer is cervical cancer. In some [embodimentexample](#), the cancer is prostate cancer. In some [embodimentexamples](#), the cancer is pancreatic cancer. In some [embodimentexamples](#), the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer. In some [embodimentexamples](#), the cancer is glioblastoma. In some [embodimentexamples](#), the cancer is lung cancer. In some [embodimentexamples](#), the cancer is bladder cancer. In some [embodimentexamples](#), the cancer is melanoma. In some [embodimentexamples](#), the cancer is kidney cancer.

[00132] In some [embodimentexamples](#), the disease or condition involves neovascularization. In some [embodimentexamples](#), the disease or condition involving neovascularization is age-related

macular degeneration (AMD), diabetic retinopathy, or cancer. In some [embodimentexamples](#), the disease or condition involves vascular inflammation.

[00133] In some [embodimentexamples](#), the method further comprises administering one or more additional therapeutic agents to the subject. In some [embodimentexamples](#), the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody. In some [embodimentexamples](#), the additional therapeutic agent is formulated in a different pharmaceutical composition from the antibody. In some [embodimentexamples](#), the additional therapeutic agent is administered prior to administering the antibody. In some [embodimentexamples](#), the additional therapeutic agent is administered after administering the antibody. In some [embodimentexamples](#), the additional therapeutic agent is administered contemporaneously with the antibody.

[00134] In another [aspectexample](#), provided herein is a method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) receiving a sample from the subject; and (b) detecting the presence or the level of TF in the sample by contacting the sample with any antibody above.

[00135] In some [embodimentexamples](#), the disease or condition is cancer. In some [embodimentexamples](#), the cancer is head and neck cancer. In some [embodimentexamples](#), the cancer is ovarian cancer. In some [embodimentexamples](#), the cancer is gastric cancer. In some [embodimentexamples](#), the cancer is esophageal cancer. In some [embodimentexamples](#), the cancer is cervical cancer. In some [embodimentexamples](#), the cancer is prostate cancer. In some [embodimentexamples](#), the cancer is pancreatic cancer. In some [embodimentexamples](#), the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer. In some [embodimentexamples](#), the cancer is glioblastoma. In some [embodimentexamples](#), the cancer is lung cancer. In some [embodimentexamples](#), the cancer is bladder cancer. In some [embodimentexamples](#), the cancer is melanoma. In some [embodimentexamples](#), the cancer is kidney cancer.

[00136] In some [embodimentexamples](#), the disease or condition involves neovascularization. In some [embodimentexamples](#), the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer. In some [embodimentexamples](#), the disease or condition involves vascular inflammation.

[00137] In another [aspectexample](#), provided herein is a method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) administering to the subject any antibody above; and (b) detecting the presence or the level of TF in the subject.

[00138] In some [embodimentexamples](#), the disease or condition is cancer. In some [embodimentexamples](#), the cancer is head and neck cancer. In some [embodimentexamples](#), the cancer is ovarian cancer. In some [embodimentexamples](#), the cancer is gastric cancer. In some [embodimentexamples](#), the cancer is

esophageal cancer. In some [embodimentexamples](#), the cancer is cervical cancer. In some [embodimentexamples](#), the cancer is prostate cancer. In some [embodimentexamples](#), the cancer is pancreatic cancer. In some [embodimentexamples](#), the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer. In some [embodimentexamples](#), the cancer is glioblastoma. In some [embodimentexamples](#), the cancer is lung cancer. In some [embodimentexamples](#), the cancer is bladder cancer. In some [embodimentexamples](#), the cancer is melanoma. In some [embodimentexamples](#), the cancer is kidney cancer.

[00139] In some [embodimentexamples](#), the disease or condition involves neovascularization. In some [embodimentexamples](#), the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer. In some [embodimentexamples](#), the disease or condition involves vascular inflammation.

[00140] In another aspect, provided herein is a kit comprising any antibody above or the pharmaceutical composition above and instructions for use.

[00141] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody binds to the extracellular domain of human Tissue Factor (TF) at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa.

[00142] In some [embodimentexamples](#), (1) the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00143] In some [embodimentexamples](#), (1) the antibody inhibits human thrombin generation to a lesser extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00144] In some [embodimentexamples](#), (1) the antibody allows human thrombin generation to a greater extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00145] In some [embodimentexamples](#), (1) the antibody inhibits human thrombin generation by a lesser amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00146] In some [embodimentexamples](#), (1) the antibody allows human thrombin generation by a greater amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and (2) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00147] In some [embodimentexamples](#), the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:784.

[00148] In some [embodimentexamples](#), the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:872; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:873; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:874; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:875; a V_L-CDR2 comprising the

sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.

[00149] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.

[00150] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[00151] In some [embodimentexamples](#), the antibody inhibits human thrombin generation to a lesser extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[00152] In some [embodimentexamples](#), the antibody allows human thrombin generation to a greater extent as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[00153] In some [embodimentexamples](#), the antibody inhibits human thrombin generation by a lesser amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[00154] In some [embodimentexamples](#), the antibody allows human thrombin generation by a greater amount as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.

[00155] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA). In some [embodimentexamples](#), the antibody does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control. In some [embodimentexamples](#), the antibody does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control. In some [embodimentexamples](#), the antibody does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an

isotype control. In some [embodimentexamples](#), the antibody allows human thrombin generation as determined by thrombin generation assay (TGA). In some [embodimentexamples](#), the antibody maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control. In some [embodimentexamples](#), the antibody maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control. In some [embodimentexamples](#), the antibody preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.

[00156] In some [embodimentexamples](#), the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX. In some [embodimentexamples](#), the antibody does not interfere with the ability of TF:FVIIa to convert FX into FXa.

[00157] In some [embodimentexamples](#), the antibody does not compete for binding to human TF with human FVIIa.

[00158] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), allows human thrombin generation as determined by thrombin generation assay (TGA), binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[00159] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[00160] In some [embodimentexamples](#), the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA),

maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

[00161] In some [embodimentexamples](#), the antibody inhibits FVIIa-dependent TF signaling.

[00162] In some [embodimentexamples](#), the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N.

[00163] In some [embodimentexamples](#), the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.

[00164] In some [embodimentexamples](#), the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00165] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the

median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00166] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00167] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00168] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00169] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00170] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the

extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00171] In some [embodiment examples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00172] In some [embodiment examples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00173] In some [embodiment examples](#), the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00174] In some [embodiment examples](#), the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding

between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some ~~embodiment~~examples, the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.

[00175] In some ~~embodiment~~examples, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain

with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, and wherein the

binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00176] In some [embodimentexamples](#), the antibody binds to cynomolgus TF. In some [embodimentexamples](#), the antibody binds to mouse TF. In some [embodimentexamples](#), the antibody binds to rabbit TF. In some [embodimentexamples](#), the antibody binds to pig TF.

[00177] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); and(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00178] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); and(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00179] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the

antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00180] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00181] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) binds to cynomolgus TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in

SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00182] In some [embodimentexamples](#), the antibody: (a) allows human thrombin generation as determined by thrombin generation assay (TGA); (b) binds to cynomolgus TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some [embodimentexamples](#), the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

[00183] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) allows human thrombin generation as determined by thrombin generation assay (TGA); (c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (e) does not compete for binding to human TF with FVIIa; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus TF; (h) binds to mouse TF; and (i) binds to rabbit TF.

[00184] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by thrombin generation assay (TGA); (d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) binds human TF at a human TF binding site that is distinct from a human TF binding site

bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (g) does not compete for binding to human TF with FVIIa; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus TF; (j) binds to mouse TF; and (k) binds to rabbit TF.

[00185] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; and (o) binds to rabbit TF.

[00186] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) allows human thrombin generation as determined by thrombin generation assay (TGA); (c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (e) does not compete for binding to human TF with FVIIa; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus TF; (h) binds to mouse TF; (i) binds to rabbit TF; and (j) binds to pig TF.

[00187] In some [embodimentexamples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by thrombin generation assay (TGA); (d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX into

FXa; (g) does not compete for binding to human TF with FVIIa; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus TF; (j) binds to mouse TF; (k) binds to rabbit TF; and (l) binds to pig TF.

[00188] In some [embodiment examples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; and (p) binds to pig TF.

[00189] In some [embodiment examples](#), the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to

cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to pig TF; (q) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (r) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (s) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (t) the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (u) the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (v) the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (w) the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in

SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (x) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (y) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (z) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (aa) the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (bb) the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00190] In some ~~embodiment~~examples, the antibody: (a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); (b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by thrombin generation assay (TGA); (f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control; (g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control; (i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX into FXa; (k) does not compete for binding to human TF with FVIIa; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to pig TF; (q) the binding between the antibody and a variant TF extracellular domain comprising a mutation K149N of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (r) the binding between the antibody and a variant TF extracellular domain comprising a mutation K68N of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (s) the binding between the antibody and a variant TF extracellular domain comprising mutations N171H and T197K of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (t) the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the

median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (u) the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (v) the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (w) the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (x) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (y) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (z) the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of

TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; (aa) the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and (bb) the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00191] In some [embodiment examples](#), the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00192] In some [embodiment examples](#), the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[00193] In some [embodiment examples](#), the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00194] In some [embodiment examples](#), the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00195] In some [embodimentexamples](#), the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[00196] In some [embodimentexamples](#), the antibody binds to the same human TF epitope bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00197] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some [embodimentexamples](#), the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

[00198] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

[00199] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00200] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some [embodimentexamples](#), the antibody comprises

all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8. In some [embodimentexample](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.

[00201] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:113 and a V_L sequence of SEQ ID NO:114. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:151 and a V_L sequence of SEQ ID NO:152. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:189 and a V_L sequence of SEQ ID NO:190. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:836 and a V_L sequence of SEQ ID NO:837. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:227 and a V_L sequence of SEQ ID NO:228. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:265 and a V_L sequence of SEQ ID NO:266. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:303 and a V_L sequence of SEQ ID NO:304. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:455 and a V_L sequence of SEQ ID NO:456. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:493 and a V_L sequence of SEQ ID NO:494. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:531 and a V_L sequence of SEQ ID NO:532. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:569 and a V_L sequence of SEQ ID NO:570. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:607 and a V_L sequence of SEQ ID NO:608. In some [embodimentexample](#), the antibody comprises a V_H sequence of SEQ ID NO:645

and a V_L sequence of SEQ ID NO:646. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:683 and a V_L sequence of SEQ ID NO:684. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:721 and a V_L sequence of SEQ ID NO:722.

[00202] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.

[00203] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:763 and a V_L sequence of SEQ ID NO:764. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:868 and a V_L sequence of SEQ ID NO:869. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:870 and a V_L sequence of SEQ ID NO:871. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:769 and a V_L sequence of SEQ ID NO:770.

[00204] In some [embodimentexamples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9,

the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some [embodiment examples](#), the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9. In some [embodiment examples](#), the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00205] In some [embodiment examples](#), the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some [embodiment examples](#), the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9. In some [embodiment examples](#), the antibody consists of: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

[00206] In another [aspect example](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody competes for binding to human TF with: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

[00207] In some [embodiment examples](#), the antibody inhibits FVIIa-dependent TF signaling.

[00208] In some [embodiment examples](#), the antibody binds to cynomolgus TF.

[00209] In some [embodiment examples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the

median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00210] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00211] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00212] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00213] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and the binding between the antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00214] In some [embodimentexamples](#), the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

[00215] In some [embodimentexamples](#), the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E. In some [embodimentexamples](#), the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

[00216] In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1F. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1G. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29D. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29E. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 39A. In some [embodimentexamples](#), the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 54E.

[00217] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:37 and a V_L sequence of SEQ ID NO:38. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:75 and a V_L sequence of SEQ ID NO:76. In some [embodimentexamples](#), the

antibody comprises a V_H sequence of SEQ ID NO:341 and a V_L sequence of SEQ ID NO:342. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:379 and a V_L sequence of SEQ ID NO:380. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:417 and a V_L sequence of SEQ ID NO:418. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:759 and a V_L sequence of SEQ ID NO:760.

[00218] In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796. In some [embodimentexamples](#), the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.

[00219] In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:761 and a V_L sequence of SEQ ID NO:762. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:765 and a V_L sequence of SEQ ID NO:766. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:767 and a V_L sequence of SEQ ID NO:768. In some [embodimentexamples](#), the antibody comprises a V_H sequence of SEQ ID NO:771 and a V_L sequence of SEQ ID NO:772.

[00220] In some [embodimentexamples](#), the antibody comprises: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E. In some [embodimentexamples](#), the antibody consists of: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

[00221] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778.

[00222] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.

[00223] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790.

[00224] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2

comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796.

[00225] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.

[00226] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.

[00227] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.

[00228] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising

the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.

[00229] In some [embodimentexamples](#), the antibody is human, humanized, or chimeric.

[00230] In some [embodimentexamples](#), the antibody binds to human TF with a K_D of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM or 0.1 nM, as measured by Octet QK384 or Biacore assay.

[00231] In some [embodimentexamples](#), the antibody is a monoclonal antibody.

[00232] In some [embodimentexamples](#), the antibody is multispecific.

[00233] In some [embodimentexamples](#), the antibody is a Fab, Fab', F(ab')₂, Fv, scFv, (scFv)₂, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody.

[00234] In some [embodimentexamples](#), the antibody comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4. In some [embodimentexamples](#), the antibody comprises a heavy chain constant region of IgG1. In some [embodimentexamples](#), the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or decreased effector function, compared with the Fc without the one or more modifications.

[00235] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody competes for binding to human TF with any antibody above.

[00236] In another [aspectexample](#), provided herein is an antibody-drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody binds the human TF epitope bound by any antibody above.

[00237] In some [embodimentexamples](#), the cytotoxic agent comprises an anti-angiogenic agent, a pro-apoptotic agent, an anti-mitotic agent, an anti-kinase agent, an alkylating agent, a hormone, a hormone agonist, a hormone antagonist, a chemokine, a drug, a prodrug, a toxin, an enzyme, an antimetabolite, an antibiotic, an alkaloid, or a radioactive isotope. In some

[embodimentexamples](#), the cytotoxic agent comprises at least one of: calicheamycin, camptothecin, carboplatin, irinotecan, SN-38, carboplatin, camptothecin, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, doxorubicin, etoposide, idarubicin, topotecan, vinca alkaloid, maytansinoid, maytansinoid analog, pyrrolobenzodiazepine, taxoid, duocarmycin, dolastatin, and auristatin.

[00238] In some [embodimentexamples](#), the linker comprises a labile linker, an acid labile linker, a photolabile linker, a charged linker, a disulfide-containing linker, a peptidase-sensitive linker, a β -glucuronide-linker, a dimethyl linker, a thio-ether linker, or a hydrophilic linker. In some [embodimentexamples](#), the linker is a cleavable linker. In some [embodimentexamples](#), the linker is a non-cleavable linker.

[00239] In another [aspectexample](#), provided herein is a pharmaceutical composition comprising any antibody-drug conjugate above and a pharmaceutically acceptable excipient.

[00240] In another [aspectexample](#), provided herein is a method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of any antibody-drug conjugate above or the pharmaceutical composition above.

[00241] In some [embodimentexamples](#), the disease or condition is cancer. In some [embodimentexamples](#), the cancer is head and neck cancer. In some [embodimentexamples](#), the cancer is ovarian cancer. In some [embodimentexamples](#), the cancer is gastric cancer. In some [embodimentexamples](#), the cancer is esophageal cancer. In some [embodimentexample](#), the cancer is cervical cancer. In some [embodimentexamples](#), the cancer is prostate cancer. In some [embodimentexamples](#), the cancer is pancreatic cancer. In some [embodimentexamples](#), the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer. In some [embodimentexamples](#), the cancer is glioblastoma. In some [embodimentexamples](#), the cancer is lung cancer. In some [embodimentexamples](#), the cancer is bladder cancer. In some [embodimentexamples](#), the cancer is melanoma. In some [embodimentexamples](#), the cancer is kidney cancer.

[00242] In some [embodimentexample](#), the method further comprises administering one or more additional therapeutic agents to the subject. In some [embodimentexamples](#), the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody-drug conjugate. In some [embodimentexamples](#), the additional therapeutic agent is formulated in a different pharmaceutical composition from the antibody-drug conjugate. In some [embodimentexamples](#), the additional therapeutic agent is administered prior to administering the antibody-drug conjugate. In some [embodimentexamples](#), the additional therapeutic agent is administered after

administering the antibody-drug conjugate. In some [embodimentexamples](#), the additional therapeutic agent is administered contemporaneously with the antibody-drug conjugate.

[00243] In another [aspectexample](#), provided herein is a method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) administering to the subject any antibody-drug conjugate above; and (b) detecting the presence or the level of TF in the subject.

[00244] In some [embodimentexamples](#), the disease or condition is cancer. In some [embodimentexamples](#), the cancer is head and neck cancer. In some [embodimentexamples](#), the cancer is ovarian cancer. In some [embodimentexamples](#), the cancer is gastric cancer. In some [embodimentexamples](#), the cancer is esophageal cancer. In some [embodimentexamples](#), the cancer is cervical cancer. In some [embodimentexamples](#), the cancer is prostate cancer. In some [embodimentexamples](#), the cancer is pancreatic cancer. In some [embodimentexamples](#), the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer. In some [embodimentexamples](#), the cancer is glioblastoma. In some [embodimentexamples](#), the cancer is lung cancer. In some [embodimentexamples](#), the cancer is bladder cancer. In some [embodimentexamples](#), the cancer is melanoma. In some [embodimentexamples](#), the cancer is kidney cancer.

[00245] In another [aspectexample](#), provided herein is a kit comprising any antibody-drug conjugate above or the pharmaceutical composition above and instructions for use.

BRIEF DESCRIPTION OF THE DRAWINGS

[00246] These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:

[00247] **Figures 1A and 1B** show binding of anti-TF antibodies to human TF-positive cells. **Figure 1A** shows the median fluorescence intensity (MFI) of antibody bound to HCT-116 cells plotted against concentrations of antibodies from groups 1, 25, and 29 and the reportable cell EC₅₀. **Figure 1B** shows the median fluorescence intensity of antibody bound to HCT-116 cells plotted against concentrations of antibodies from groups 39, 43, and 54 and the reportable cell EC₅₀. The isotype control in **Figure 1B** applies to both **Figures 1A and 1B**.

[00248] **Figures 2A and 2B** show binding of anti-TF antibodies to mouse TF-positive cells. **Figure 2A** shows the median fluorescence intensity (MFI) of antibody bound to CHO cells recombinantly expressing mouse TF (CHO-mTF) plotted against concentrations of antibodies from groups 1, 25, and 29 and the reportable cell EC₅₀. **Figure 2B** shows the

CLAIMS

~~1. An isolated human antibody which binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa.~~

~~2. The isolated human antibody of claim 0, wherein~~

~~(1) —the isolated antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822, and wherein~~

~~(2) —the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live-cell staining assay.~~

~~3. The isolated human antibody of claim 0 or 2, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:784.~~

~~4. The isolated human antibody of any one of claims 0 to 3, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:872; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:873; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:874; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:875; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:877.~~

~~5. The isolated human antibody of any one of claims 0 to 3, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:878; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:879; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:880; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:881; a V_L-~~

~~CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.~~

~~6. The isolated human antibody of claim 0, wherein the isolated antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822.~~

~~7. The isolated human antibody of claim 0, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA).~~

~~8. The isolated human antibody of claim 7, wherein the antibody does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control.~~

~~9. The isolated human antibody of claim 7 or 8, wherein the antibody does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control.~~

~~10. The isolated human antibody of any one of claims 7 to 9, wherein the antibody does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.~~

~~11. The isolated human antibody of any of the above claims, wherein the antibody allows human thrombin generation as determined by thrombin generation assay (TGA).~~

~~12. The isolated human antibody of claim 11, wherein the antibody maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control.~~

~~13. The isolated human antibody of claim 11 or 12, wherein the antibody maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control.~~

~~14. The isolated human antibody of any one of claims 11 to 13, wherein the antibody preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.~~

~~15. The isolated human antibody of any of the above claims, wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX.~~

~~16. The isolated human antibody of any of the above claims, wherein the antibody does not interfere with the ability of TF:FVIIa to convert FX into FXa.~~

~~17. The isolated human antibody of any of the above claims, wherein the antibody does not compete for binding to human TF with human FVIIa.~~

~~18. The isolated human antibody of any of the above claims, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), allows human thrombin generation as determined by thrombin generation assay (TGA), binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.~~

~~19. The isolated human antibody of any of the above claims, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.~~

~~20. The isolated human antibody of any of the above claims, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF~~

~~binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.~~

~~21. The isolated human antibody of any of the above claims, wherein the antibody inhibits FVIIa dependent TF signaling.~~

~~22. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~23. The isolated human antibody of claim 22, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N.~~

~~24. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~25. The isolated human antibody of claim 24, wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.~~

~~26. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~27. The isolated human antibody of claim 26, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~28. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the~~

~~sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~29. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~30. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~31. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~32. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in~~

~~SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~33. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~34. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~35. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~36. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~37. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid~~

~~residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ~~

~~ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay~~

~~38. The isolated human antibody of claim 37, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.~~

~~39. The isolated human antibody of any of the above claims, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~40. The isolated human antibody of claim 39, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N;~~

~~wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N; and~~

~~wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~41. The isolated human antibody of any of the above claims, wherein the antibody binds to cynomolgus TF.~~

~~42. The isolated human antibody of any of the above claims, wherein the antibody binds to mouse TF.~~

~~43. The isolated human antibody of any of the above claims, wherein the antibody binds to rabbit TF.~~

~~44. The isolated human antibody of any of the above claims, wherein the antibody binds to pig TF.~~

~~45. The isolated human antibody of any of the above claims, wherein the antibody reduces lesion size in a swine choroidal neovascularization (CNV) model.~~

~~46. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); and~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined~~

by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~47. The isolated human antibody of claim 46, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~48. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA); and~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~49. The isolated human antibody of claim 48, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~50. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~51. The isolated human antibody of claim 50, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~52. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~53. The isolated human antibody of claim 52, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~54. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) binds to cynomolgus TF;~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of~~

~~the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~55. The isolated human antibody of claim 54, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~56. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) binds to cynomolgus TF;~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~57. The isolated human antibody of claim 56, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~58. The isolated human antibody of any of the above claims, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(e) does not compete for binding to human TF with FVIIa;~~
- ~~(f) inhibits FVIIa dependent TF signaling;~~
- ~~(g) binds to cynomolgus TF;~~
- ~~(h) binds to mouse TF; and~~
- ~~(i) binds to rabbit TF.~~

59. ~~The isolated human antibody of any of the above claims, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(c) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(f) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(g) does not compete for binding to human TF with FVIIa;~~
- ~~(h) inhibits FVIIa dependent TF signaling;~~
- ~~(i) binds to cynomolgus TF;~~
- ~~(j) binds to mouse TF; and~~

(k) binds to rabbit TF.

60. The isolated human antibody of any of the above claims, wherein the antibody:

(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);

(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;

(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;

(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;

(e) allows human thrombin generation as determined by thrombin generation assay (TGA);

(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;

(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;

(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;

(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;

(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;

(k) does not compete for binding to human TF with FVIIa;

(l) inhibits FVIIa dependent TF signaling;

(m) binds to cynomolgus TF;

(n) binds to mouse TF; and

(o) binds to rabbit TF.

61. The isolated human antibody of any of the above claims, wherein the antibody:

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(e) does not compete for binding to human TF with FVIIa;~~
- ~~(f) inhibits FVIIa dependent TF signaling;~~
- ~~(g) binds to cynomolgus TF;~~
- ~~(h) binds to mouse TF;~~
- ~~(i) binds to rabbit TF;~~
- ~~(j) binds to pig TF;~~
- ~~and (k) reduces lesion size in a swine choroidal neovascularization (CNV) model.~~

62. ~~The isolated human antibody of any of the above claims, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(c) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(f) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(g) does not compete for binding to human TF with FVIIa;~~
- ~~(h) inhibits FVIIa dependent TF signaling;~~

- ~~(i) binds to cynomolgus TF;~~
- ~~(j) binds to mouse TF;~~
- ~~(k) binds to rabbit TF;~~
- ~~(l) binds to pig TF;~~
- ~~and (m) reduces lesion size in a swine choroidal neovascularization (CNV) model.~~

63. ~~The isolated human antibody of any of the above claims, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa-dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~

- ~~(n) binds to mouse TF;~~
- ~~(o) binds to rabbit TF;~~
- ~~(p) binds to pig TF;~~
- ~~and (q) reduces lesion size in a swine choroidal neovascularization (CNV) model.~~

64. ~~The isolated human antibody of any of the above claims, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF;~~

~~(o) binds to rabbit TF;~~

~~(p) binds to pig TF;~~

~~(q) reduces lesion size in a swine choroidal neovascularization (CNV) model;~~

~~(r) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(s) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(t) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(u) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(v) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID~~

~~NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(w) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(x) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(y) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(z) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(aa) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(bb) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and~~

~~(cc) wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~65. The isolated human antibody of any of the above claims, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak Ha) compared to an isotype control;~~

~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~

~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF;~~
- ~~(o) binds to rabbit TF;~~
- ~~(p) binds to pig TF;~~
- ~~(q) reduces lesion size in a swine choroidal neovascularization (CNV) model;~~
- ~~(r) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation K149N of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~
- ~~(s) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation K68N of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(t) wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations N171H and T197K of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(u) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(v) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(w) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(x) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the~~

median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;

~~(y) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(z) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(aa) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;~~

~~(bb) wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and~~

~~(cc) wherein the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838-~~

replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

~~66. The isolated human antibody of any of the above claims, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~67. The isolated human antibody of claim 64, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~68. The isolated human antibody of claim 64, wherein the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~69. The isolated human antibody of any of the above claims, wherein the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~70. The isolated human antibody of claim 69, wherein the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~71. The isolated human antibody of claim 69, wherein the antibody binds to the same human TF epitope bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~72. The isolated human antibody of any of the above claims, comprising all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~73. The isolated human antibody of claim 72, wherein the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.~~

~~74. The isolated human antibody of claim 72 or 73, comprising all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~75. The isolated human antibody of claim 72 or 73, comprising all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~76. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A.~~

~~77. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3.~~

~~78. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5.~~

- ~~79. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T.~~
- ~~80. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G.~~
- ~~81. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1.~~
- ~~82. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.~~
- ~~83. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.~~
- ~~84. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1.~~
- ~~85. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7.~~
- ~~86. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D.~~
- ~~87. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7.~~
- ~~88. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8.~~
- ~~89. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E.~~
- ~~90. The isolated human antibody of claim 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.~~
- ~~91. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:113 and a V_L-sequence of SEQ ID NO:114.~~
- ~~92. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:151 and a V_L-sequence of SEQ ID NO:152.~~

- ~~93. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:189 and a V_L-sequence of SEQ ID NO:190.~~
- ~~94. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:836 and a V_L-sequence of SEQ ID NO:837.~~
- ~~95. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:227 and a V_L-sequence of SEQ ID NO:228.~~
- ~~96. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:265 and a V_L-sequence of SEQ ID NO:266.~~
- ~~97. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:303 and a V_L-sequence of SEQ ID NO:304.~~
- ~~98. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:455 and a V_L-sequence of SEQ ID NO:456.~~
- ~~99. The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:493 and a V_L-sequence of SEQ ID NO:494.~~
- ~~100.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:531 and a V_L-sequence of SEQ ID NO:532.~~
- ~~101.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:569 and a V_L-sequence of SEQ ID NO:570.~~
- ~~102.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:607 and a V_L-sequence of SEQ ID NO:608.~~
- ~~103.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:645 and a V_L-sequence of SEQ ID NO:646.~~
- ~~104.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:683 and a V_L-sequence of SEQ ID NO:684.~~
- ~~105.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H-sequence of SEQ ID NO:721 and a V_L-sequence of SEQ ID NO:722.~~
- ~~106.—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence~~

set forth in SEQ ID NO:781; a VL CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:784.

~~107.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:877.

~~108.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:883.

~~109.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:802.

~~110.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H sequence of SEQ ID NO:763 and a V_L sequence of SEQ ID NO:764.

~~111.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H sequence of SEQ ID NO:868 and a V_L sequence of SEQ ID NO:869.

~~112.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H sequence of SEQ ID NO:870 and a V_L sequence of SEQ ID NO:871.

~~113.~~—The isolated human antibody of any one of claims 0 to 73, wherein the antibody comprises a V_H sequence of SEQ ID NO:769 and a V_L sequence of SEQ ID NO:770.

~~114.~~—The isolated human antibody of any of the above claims, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody

~~designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**115.**—The isolated human antibody of claim 114, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~**116.**—The isolated human antibody of claim 114, wherein the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**117.**—The isolated human antibody of any of the above claims, wherein the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**118.**—The isolated human antibody of claim 117, wherein the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~**119.**—The isolated human antibody of claim 117, wherein the antibody consists of: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**120.**—An isolated antibody comprising all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T,~~

~~the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~121. The isolated antibody of claim 120, wherein the antibody is human, humanized, or chimeric.~~

~~122. The isolated antibody of claim 120 or 121, wherein the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.~~

~~123. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~124. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A.~~

~~125. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3.~~

~~126. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5.~~

~~127. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5 T.~~

~~128. The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G.~~

~~129.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1.~~

~~130.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.~~

~~131.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~132.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.~~

~~133.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1.~~

~~134.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7.~~

~~135.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D.~~

~~136.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7.~~

~~137.—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8.~~

~~138.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E.

~~139.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.

~~140.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:113 and a V_L-sequence of SEQ ID NO:114.

~~141.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:151 and a V_L-sequence of SEQ ID NO:152.

~~142.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:189 and a V_L-sequence of SEQ ID NO:190.

~~143.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:836 and a V_L-sequence of SEQ ID NO:837.

~~144.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:227 and a V_L-sequence of SEQ ID NO:228.

~~145.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:265 and a V_L-sequence of SEQ ID NO:266.

~~146.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:303 and a V_L-sequence of SEQ ID NO:304.

~~147.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:455 and a V_L-sequence of SEQ ID NO:456.

~~148.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:493 and a V_L-sequence of SEQ ID NO:494.

~~149.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:531 and a V_L-sequence of SEQ ID NO:532.

~~150.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:569 and a V_L-sequence of SEQ ID NO:570.

~~151.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:607 and a V_L-sequence of SEQ ID NO:608.

~~152.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:645 and a V_L-sequence of SEQ ID NO:646.

~~153.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:683 and a V_L-sequence of SEQ ID NO:684.

~~154.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H-sequence of SEQ ID NO:721 and a V_L-sequence of SEQ ID NO:722.

~~155.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:784.

~~156.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:872; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:873; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:874; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:875; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:877.

~~157.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:878; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:879; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:880; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:881; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:883.

~~158.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:797; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:798; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:799; a V_L-CDR1 comprising the sequence set forth in SEQ ID

NO:800; a VL CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:802.

~~159.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H sequence of SEQ ID NO:763 and a V_L sequence of SEQ ID NO:764.

~~160.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H sequence of SEQ ID NO:868 and a V_L sequence of SEQ ID NO:869.

~~161.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H sequence of SEQ ID NO:870 and a V_L sequence of SEQ ID NO:871.

~~162.~~—The isolated antibody of any one of claims 120 to 122, wherein the antibody comprises a V_H sequence of SEQ ID NO:769 and a V_L sequence of SEQ ID NO:770.

~~163.~~—The isolated antibody of any one of claims 120 to 162, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

~~164.~~—The isolated antibody of any one of claim 163, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

~~165.~~—The isolated antibody of any one of claim 163, wherein the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

~~166.~~—The isolated antibody of any one of claims 120 to 163, wherein the antibody consists: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

~~167.~~—The isolated antibody of any one of claim 166, wherein the antibody consists: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.

~~168.~~—The isolated antibody of any one of claim 166, wherein the antibody consists: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

~~169.~~—An isolated antibody that competes for binding to human TF with: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.

~~170.~~—The isolated antibody of claim 169, wherein the antibody is human, humanized, or chimeric.

~~171.~~—The isolated antibody of claim 169 or 170, wherein the antibody inhibits FVIIa-dependent TF signaling.

~~172.~~—The isolated antibody of any one of claims 169 to 171, wherein the antibody binds to cynomolgus TF.

~~173.~~—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

~~174.~~—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.

~~175.—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~176.—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~177.—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~178.—The isolated antibody of any one of claims 169 to 172, wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the~~

~~binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.~~

~~**179.**—The isolated antibody of any one of claims 169 to 178, comprising all three heavy-chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E.~~

~~**180.**—The isolated antibody of claim 179, wherein the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.~~

~~**181.**—The isolated antibody of claim 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1F.~~

~~**182.**—The isolated antibody of claim 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1G.~~

~~**183.**—The isolated antibody of claim 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29D.~~

~~**184.**—The isolated antibody of claim 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29E.~~

~~185.~~—The isolated antibody of claim ~~179~~ or ~~180~~, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated ~~39A~~.

~~186.~~—The isolated antibody of claim ~~179~~ or ~~180~~, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated ~~54E~~.

~~187.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:37 and a V_L -sequence of SEQ ID NO:38.

~~188.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:75 and a V_L -sequence of SEQ ID NO:76.

~~189.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:341 and a V_L -sequence of SEQ ID NO:342.

~~190.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:379 and a V_L -sequence of SEQ ID NO:380.

~~191.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:417 and a V_L -sequence of SEQ ID NO:418.

~~192.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises a V_H -sequence of SEQ ID NO:759 and a V_L -sequence of SEQ ID NO:760.

~~193.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises: a V_H -CDR1 comprising the sequence set forth in SEQ ID NO:773; a V_H -CDR2 comprising the sequence set forth in SEQ ID NO:774; a V_H -CDR3 comprising the sequence set forth in SEQ ID NO:775; a V_L -CDR1 comprising the sequence set forth in SEQ ID NO:776; a V_L -CDR2 comprising the sequence set forth in SEQ ID NO:777; and a V_L -CDR3 comprising the sequence set forth in SEQ ID NO:778.

~~194.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises: a V_H -CDR1 comprising the sequence set forth in SEQ ID NO:785; a V_H -CDR2 comprising the sequence set forth in SEQ ID NO:786; a V_H -CDR3 comprising the sequence set forth in SEQ ID NO:787; a V_L -CDR1 comprising the sequence set forth in SEQ ID NO:788; a V_L -CDR2 comprising the sequence set forth in SEQ ID NO:789; and a V_L -CDR3 comprising the sequence set forth in SEQ ID NO:790.

~~195.~~—The isolated antibody of any one of claims ~~169~~ to ~~180~~, wherein the antibody comprises: a V_H -CDR1 comprising the sequence set forth in SEQ ID NO:791; a V_H -CDR2

~~comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796.~~

~~**196.**—The isolated antibody of any one of claims 169 to 180, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.~~

~~**197.**—The isolated antibody of any one of claims 169 to 180, wherein the antibody comprises a V_H-sequence of SEQ ID NO:761 and a V_L-sequence of SEQ ID NO:762.~~

~~**198.**—The isolated antibody of any one of claims 169 to 180, wherein the antibody comprises a V_H-sequence of SEQ ID NO:765 and a V_L-sequence of SEQ ID NO:766.~~

~~**199.**—The isolated antibody of any one of claims 169 to 180, wherein the antibody comprises a V_H-sequence of SEQ ID NO:767 and a V_L-sequence of SEQ ID NO:768.~~

~~**200.**—The isolated antibody of any one of claims 169 to 180, wherein the antibody comprises a V_H-sequence of SEQ ID NO:771 and a V_L-sequence of SEQ ID NO:772.~~

~~**201.**—The isolated antibody of any one of claims 169 to 200, wherein the antibody comprises: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.~~

~~**202.**—The isolated antibody of any one of claims 169 to 201, wherein the antibody consists of: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.~~

~~**203.**—An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778.~~

~~204. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.~~

~~205. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790.~~

~~206. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796.~~

~~207. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.~~

~~208. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.~~

~~209. —An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.~~

~~210.—An isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.~~

~~211.—The isolated antibody of any of the above claims, wherein the antibody binds to human TF with a K_D of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM or 0.1 nM, as measured by Octet QK384 or Biacore assay.~~

~~212.—The isolated antibody of any of the above claims, wherein the antibody is a monoclonal antibody.~~

~~213.—The isolated antibody of any of the above claims, wherein the antibody is multispecific.~~

~~214.—The isolated antibody of any of the above claims, wherein the antibody is a Fab, Fab', $F(ab')_2$, Fv, scFv, (scFv)₂, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody.~~

~~215.—The isolated antibody of any of the above claims, wherein the antibody comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc.~~

~~216.—The isolated antibody of claim 215, wherein the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.~~

~~217.—The isolated antibody of claim 216, wherein the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.~~

~~218.—The isolated antibody of claim 217, wherein the antibody comprises a heavy chain constant region of IgG1.~~

~~219.—The isolated antibody of any one of claims 215 to 218, wherein the Fc comprises one or more modifications, wherein the one or more modifications result in increased half life, increased antibody dependent cellular cytotoxicity (ADCC), increased antibody dependent cellular phagocytosis (ADCP), increased complement dependent cytotoxicity (CDC), or decreased effector function, compared with the Fc without the one or more modifications.~~

~~220.—An isolated antibody that competes for binding to human TF with the antibody of any of the above claims.~~

- ~~221.—An isolated antibody that binds the human TF epitope bound by the antibody of any of the above claims.~~
- ~~222.—An isolated polynucleotide or set of polynucleotides encoding the antibody of any of the above claims, a V_H thereof, a V_L thereof, a light chain thereof, a heavy chain thereof, or an antigen binding portion thereof.~~
- ~~223.—A vector or set of vectors comprising the polynucleotide or set of polynucleotides of claim 222.~~
- ~~224.—A host cell comprising the polynucleotide or set of polynucleotides of claim 222 or the vector or set of vectors of claim 223.~~
- ~~225.—A method of producing an antibody comprising expressing the antibody with the host cell of claim 224 and isolating the expressed antibody.~~
- ~~226.—A pharmaceutical composition comprising the antibody of any one of claims 0 to 221 and a pharmaceutically acceptable excipient.~~
- ~~227.—A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of the antibody of any one of claims 0 to 221 or the pharmaceutical composition of claim 226.~~
- ~~228.—The method of claim 227, wherein the disease or condition is cancer.~~
- ~~229.—The method of claim 228, wherein the cancer is head and neck cancer.~~
- ~~230.—The method of claim 228, wherein the cancer is ovarian cancer.~~
- ~~231.—The method of claim 228, wherein the cancer is gastric cancer.~~
- ~~232.—The method of claim 228, wherein the cancer is esophageal cancer.~~
- ~~233.—The method of claim 228, wherein the cancer is cervical cancer.~~
- ~~234.—The method of claim 228, wherein the cancer is prostate cancer.~~
- ~~235.—The method of claim 228, wherein the cancer is pancreatic cancer.~~
- ~~236.—The method of claim 228, wherein the cancer is estrogen receptors negative (ER⁻), progesterone receptors negative (PR⁻), and HER2 negative (HER2⁻) triple negative breast cancer.~~
- ~~237.—The method of claim 228, wherein the cancer is glioblastoma.~~

- ~~238.—The method of claim 228, wherein the cancer is lung cancer.~~
- ~~239.—The method of claim 228, wherein the cancer is bladder cancer.~~
- ~~240.—The method of claim 228, wherein the cancer is melanoma.~~
- ~~241.—The method of claim 228, wherein the cancer is kidney cancer.~~
- ~~242.—The method of claim 227, wherein the disease or condition involves neovascularization.~~
- ~~243.—The method of claim 242, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.~~
- ~~244.—The method of claim 227, wherein the disease or condition involves vascular inflammation.~~
- ~~245.—The method of any one of claims 227 to 244, further comprising administering one or more additional therapeutic agents to the subject.~~
- ~~246.—The method of claim 245, wherein the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody.~~
- ~~247.—The method of claim 245, wherein the additional therapeutic agent is formulated in a different pharmaceutical composition from the antibody.~~
- ~~248.—The method of claim 245, wherein the additional therapeutic agent is administered prior to administering the antibody.~~
- ~~249.—The method of claim 245, wherein the additional therapeutic agent is administered after administering the antibody.~~
- ~~250.—The method of claim 245, wherein the additional therapeutic agent is administered contemporaneously with the antibody.~~
- ~~251.—A method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) receiving a sample from the subject; and (b) detecting the presence or the level of TF in the sample by contacting the sample with the antibody of any one of claims 0 to 221.~~
- ~~252.—The method of claim 251, wherein the disease or condition is cancer.~~
- ~~253.—The method of claim 252, wherein the cancer is head and neck cancer.~~

- ~~254. The method of claim 252, wherein the cancer is ovarian cancer.~~
- ~~255. The method of claim 252, wherein the cancer is gastric cancer.~~
- ~~256. The method of claim 252, wherein the cancer is esophageal cancer.~~
- ~~257. The method of claim 252, wherein the cancer is cervical cancer.~~
- ~~258. The method of claim 252, wherein the cancer is prostate cancer.~~
- ~~259. The method of claim 252, wherein the cancer is pancreatic cancer.~~
- ~~260. The method of claim 252, wherein the cancer is estrogen receptors negative (ER -), progesterone receptors negative (PR -), and HER2 negative (HER2 -) triple negative breast cancer.~~
- ~~261. The method of claim 252, wherein the cancer is glioblastoma.~~
- ~~262. The method of claim 252, wherein the cancer is lung cancer.~~
- ~~263. The method of claim 252, wherein the cancer is bladder cancer.~~
- ~~264. The method of claim 252, wherein the cancer is melanoma.~~
- ~~265. The method of claim 252, wherein the cancer is kidney cancer.~~
- ~~266. The method of claim 251, wherein the disease or condition involves neovascularization.~~
- ~~267. The method of claim 266, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.~~
- ~~268. The method of claim 251, wherein the disease or condition involves vascular inflammation.~~
- ~~269. A method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) administering to the subject the antibody of any one of claims 0 to 221; and (b) detecting the presence or the level of TF in the subject.~~
- ~~270. The method of claim 269, wherein the disease or condition is cancer.~~
- ~~271. The method of claim 270, wherein the cancer is head and neck cancer.~~
- ~~272. The method of claim 270, wherein the cancer is ovarian cancer.~~
- ~~273. The method of claim 270, wherein the cancer is gastric cancer.~~

- ~~274.—The method of claim 270, wherein the cancer is esophageal cancer.~~
- ~~275.—The method of claim 270, wherein the cancer is cervical cancer.~~
- ~~276.—The method of claim 270, wherein the cancer is prostate cancer.~~
- ~~277.—The method of claim 270, wherein the cancer is pancreatic cancer.~~
- ~~278.—The method of claim 270, wherein the cancer is estrogen receptors negative (ER⁻), progesterone receptors negative (PR⁻), and HER2 negative (HER2⁻) triple negative breast cancer.~~
- ~~279.—The method of claim 270, wherein the cancer is glioblastoma.~~
- ~~280.—The method of claim 270, wherein the cancer is lung cancer.~~
- ~~281.—The method of claim 270, wherein the cancer is bladder cancer.~~
- ~~282.—The method of claim 270, wherein the cancer is melanoma.~~
- ~~283.—The method of claim 270, wherein the cancer is kidney cancer.~~
- ~~284.—The method of claim 269, wherein the disease or condition involves neovascularization.~~
- ~~285.—The method of claim 284, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.~~
- ~~286.—The method of claim 269, wherein the disease or condition involves vascular inflammation.~~
- ~~287.—A kit comprising the antibody of any one of claims 0 to 221 or the pharmaceutical composition of claim 226 and instructions for use.~~
- ~~288.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody binds to the extracellular domain of human Tissue Factor (TF) at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa.~~
- ~~289.—The antibody drug conjugate of claim 288, wherein~~

~~(1) — the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H-sequence of SEQ ID NO:821 and a V_L-sequence of SEQ ID NO:822, and wherein~~

~~(2) — the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~**290.** — The antibody drug conjugate of claim 288 or 289, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:784.~~

~~**291.** — The antibody drug conjugate of any one of claims 288 to 290, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:872; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:873; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:874; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:875; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:877.~~

~~**292.** — The antibody drug conjugate of any one of claims 288 to 290, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:878; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:879; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:880; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:881; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:883.~~

~~**293.** — The antibody drug conjugate of claim 288, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA) compared to a reference antibody comprising a V_H-sequence of SEQ ID NO:821 and a V_L-sequence of SEQ ID NO:822.~~

~~294.~~—The antibody drug conjugate of claim 288, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA).

~~295.~~—The antibody drug conjugate of claim 294, wherein the antibody does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control.

~~296.~~—The antibody drug conjugate of claim 294 or 295, wherein the antibody does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control.

~~297.~~—The antibody drug conjugate of any one of claims 294 to 296, wherein the antibody does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.

~~298.~~—The antibody drug conjugate of any one of claims 288 to 297, wherein the antibody allows human thrombin generation as determined by thrombin generation assay (TGA).

~~299.~~—The antibody drug conjugate of claim 298, wherein the antibody maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control.

~~300.~~—The antibody drug conjugate of claim 298 or 299, wherein the antibody maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control.

~~301.~~—The antibody drug conjugate of any one of claims 298 to 300, wherein the antibody preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.

~~302.~~—The antibody drug conjugate of any one of claims 288 to 301, wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX.

~~303.~~—The antibody drug conjugate of any one of claims 288 to 302, wherein the antibody does not interfere with the ability of TF:FVIIa to convert FX into FXa.

~~304.~~—The antibody drug conjugate of any one of claims 288 to 303, wherein the antibody does not compete for binding to human TF with human FVIIa.

~~305.~~—The antibody drug conjugate of any one of claims 288 to 304, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), allows human thrombin generation as determined by thrombin generation assay

(TGA), binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

~~306.—The antibody drug conjugate of any one of claims 288 to 305, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.~~

~~307.—The antibody drug conjugate of any one of claims 288 to 306, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.~~

~~308.—The antibody drug conjugate of any one of claims 288 to 307, wherein the antibody inhibits FVIIa dependent TF signaling.~~

~~309.—The antibody drug conjugate of any one of claims 288 to 308, wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino~~

acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

310.—The antibody drug conjugate of claim 309, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N.

311.—The antibody drug conjugate of any one of claims 288 to 310, wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

312.—The antibody drug conjugate of claim 311, wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.

313.—The antibody drug conjugate of any one of claims 288 to 312, wherein the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

314.—The antibody drug conjugate of claim 313, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

315.—The antibody drug conjugate of any one of claims 288 to 314, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

316.—The antibody drug conjugate of any one of claims 288 to 315, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77

of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~317.—The antibody drug conjugate of any one of claims 288 to 316, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~318.—The antibody drug conjugate of any one of claims 288 to 317, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~319.—The antibody drug conjugate of any one of claims 288 to 318, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~320.—The antibody drug conjugate of any one of claims 288 to 319, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown~~

in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~321.—The antibody drug conjugate of any one of claims 288 to 320, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159–174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164–179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~322.—The antibody drug conjugate of any one of claims 288 to 321, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 167–174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172–179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~323.—The antibody drug conjugate of any one of claims 288 to 322, wherein the binding between the antibody and a rat TF extracellular domain with amino acid residues 141–194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136–189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~324.—The antibody drug conjugate of any one of claims 288 to 323, wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

325.—~~The antibody drug conjugate of claim 324, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N.~~

~~326. The antibody drug conjugate of any one of claims 288 to 325, wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838~~

is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and

wherein the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

327.—The antibody drug conjugate of claim 326, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N;

~~wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is K68N; and~~

~~wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~328. The antibody drug conjugate of any one of claims 288 to 327, wherein the antibody binds to cynomolgus TF.~~

~~329. The antibody drug conjugate of any one of claims 288 to 328, wherein the antibody binds to mouse TF.~~

~~330. The antibody drug conjugate of any one of claims 288 to 329, wherein the antibody binds to rabbit TF.~~

~~331. The antibody drug conjugate of any one of claims 288 to 330, wherein the antibody binds to pig TF.~~

~~332. The antibody drug conjugate of any one of claims 288 to 331, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); and~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~333. The antibody drug conjugate of claim 332, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~334. The antibody drug conjugate of any one of claims 288 to 333, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA); and~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined~~

by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~335. The antibody drug conjugate of claim 334, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~336. The antibody drug conjugate of any one of claims 288 to 335, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~337. The antibody drug conjugate of claim 336, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~338. The antibody drug conjugate of any one of claims 288 to 337, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the~~

median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and

(c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~339.~~—The antibody drug conjugate of claim 338, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and

the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

~~340.~~—The antibody drug conjugate of any one of claims 288 to 339, wherein the antibody:

(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);

(b) binds to cynomolgus TF;

(c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and

(d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~341.~~—The antibody drug conjugate of claim 340, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and

the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.

~~342. The antibody drug conjugate of any one of claims 288 to 341, wherein the antibody:~~

~~(a) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) binds to cynomolgus TF;~~

~~(c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~343. The antibody drug conjugate of claim 342, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is K149N; and~~

~~the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO:810 are N171H and T197K.~~

~~344. The antibody drug conjugate of any one of claims 288 to 343, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~

~~(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~

~~(e) does not compete for binding to human TF with FVIIa;~~

~~(f) inhibits FVIIa dependent TF signaling;~~

~~(g) binds to cynomolgus TF;~~

~~(h) binds to mouse TF; and~~

~~(i) binds to rabbit TF.~~

~~345. The antibody drug conjugate of any one of claims 288 to 344, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

~~(c) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

~~(e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~

~~(f) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~

~~(g) does not compete for binding to human TF with FVIIa;~~

~~(h) inhibits FVIIa dependent TF signaling;~~

~~(i) binds to cynomolgus TF;~~

~~(j) binds to mouse TF; and~~

~~(k) binds to rabbit TF.~~

~~346. The antibody drug conjugate of any one of claims 288 to 345, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~

~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~

~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa-dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF; and~~
- ~~(o) binds to rabbit TF.~~

347.—The antibody drug conjugate of any one of claims 288 to 346, wherein the antibody:

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(e) does not compete for binding to human TF with FVIIa;~~
- ~~(f) inhibits FVIIa-dependent TF signaling;~~
- ~~(g) binds to cynomolgus TF;~~
- ~~(h) binds to mouse TF;~~

~~(i) binds to rabbit TF;~~

~~and (j) binds to pig TF.~~

~~348. The antibody drug conjugate of any one of claims 288 to 347, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

~~(c) allows human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(d) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

~~(e) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~

~~(f) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~

~~(g) does not compete for binding to human TF with FVIIa;~~

~~(h) inhibits FVIIa dependent TF signaling;~~

~~(i) binds to cynomolgus TF;~~

~~(j) binds to mouse TF;~~

~~(k) binds to rabbit TF;~~

~~and (l) binds to pig TF.~~

~~349. The antibody drug conjugate of any one of claims 288 to 348, wherein the antibody:~~

~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~

~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~

~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~

- ~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF;~~
- ~~(o) binds to rabbit TF;~~
- ~~and (p) binds to pig TF.~~

350. ~~The antibody drug conjugate of any one of claims 288 to 349, wherein the antibody:~~

- ~~(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~

- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF;~~
- ~~(o) binds to rabbit TF;~~
- ~~(p) binds to pig TF;~~

~~(q) wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(r) wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(s) wherein the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID-~~

~~NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(t) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(u) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(v) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(w) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(x) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of~~

TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(y) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(z) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(aa) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and

(bb) wherein the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

351.—The antibody drug conjugate of any one of claims 288 to 350, wherein the antibody:

(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);

(b) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;

- ~~(c) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(d) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(e) allows human thrombin generation as determined by thrombin generation assay (TGA);~~
- ~~(f) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;~~
- ~~(g) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;~~
- ~~(h) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;~~
- ~~(i) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;~~
- ~~(j) does not interfere with the ability of TF:FVIIa to convert FX into FXa;~~
- ~~(k) does not compete for binding to human TF with FVIIa;~~
- ~~(l) inhibits FVIIa-dependent TF signaling;~~
- ~~(m) binds to cynomolgus TF;~~
- ~~(n) binds to mouse TF;~~
- ~~(o) binds to rabbit TF;~~
- ~~(p) binds to pig TF;~~
- ~~(q) wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation K149N of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~
- ~~(r) wherein the binding between the antibody and a variant TF extracellular domain comprising a mutation K68N of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence~~

shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(s) wherein the binding between the antibody and a variant TF extracellular domain comprising mutations N171H and T197K of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(t) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(u) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(v) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

(w) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;

~~(x) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-219 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-224 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(y) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-189 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-194 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~(z) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 159-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 164-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;~~

~~aa) wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 167-174 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 172-179 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and~~

~~(bb) wherein the binding between the antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

352.—~~The antibody-drug conjugate of any one of claims 288 to 351, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody-~~

~~designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**353.**—The antibody drug conjugate of claim 352, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~**354.**—The antibody drug conjugate of claim 352, wherein the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**355.**—The antibody drug conjugate of any one of claims 288 to 354, wherein the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**356.**—The antibody drug conjugate of claim 355, wherein the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5 T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~**357.**—The antibody drug conjugate of claim 355, wherein the antibody binds to the same human TF epitope bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**358.**—The antibody drug conjugate of any one of claims 288 to 357, wherein the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the~~

~~antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**359.**—The antibody drug conjugate of claim 358, wherein the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.~~

~~**360.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~**361.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~**362.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A.~~

~~**363.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3.~~

~~**364.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5.~~

~~**365.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T.~~

~~**366.**—The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G.~~

~~367. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1.~~

~~368. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.~~

~~369. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.~~

~~370. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1.~~

~~371. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7.~~

~~372. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D.~~

~~373. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7.~~

~~374. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8.~~

~~375. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E.~~

~~376. The antibody drug conjugate of claim 358 or 359, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.~~

~~377. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H sequence of SEQ ID NO:113 and a V_L sequence of SEQ ID NO:114.~~

~~378. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H sequence of SEQ ID NO:151 and a V_L sequence of SEQ ID NO:152.~~

~~379. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H sequence of SEQ ID NO:189 and a V_L sequence of SEQ ID NO:190.~~

~~380. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H sequence of SEQ ID NO:836 and a V_L sequence of SEQ ID NO:837.~~

~~381. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:227 and a V_L-sequence of SEQ ID NO:228.~~

~~382. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:265 and a V_L-sequence of SEQ ID NO:266.~~

~~383. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:303 and a V_L-sequence of SEQ ID NO:304.~~

~~384. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:455 and a V_L-sequence of SEQ ID NO:456.~~

~~385. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:493 and a V_L-sequence of SEQ ID NO:494.~~

~~386. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:531 and a V_L-sequence of SEQ ID NO:532.~~

~~387. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:569 and a V_L-sequence of SEQ ID NO:570.~~

~~388. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:607 and a V_L-sequence of SEQ ID NO:608.~~

~~389. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:645 and a V_L-sequence of SEQ ID NO:646.~~

~~390. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:683 and a V_L-sequence of SEQ ID NO:684.~~

~~391. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:721 and a V_L-sequence of SEQ ID NO:722.~~

~~392. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:784.~~

~~393. The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:872; a V_H-CDR2~~

~~comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.~~

~~394.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.~~

~~395.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.~~

~~396.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:763 and a V_L-sequence of SEQ ID NO:764.~~

~~397.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:868 and a V_L-sequence of SEQ ID NO:869.~~

~~398.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:870 and a V_L-sequence of SEQ ID NO:871.~~

~~399.—The antibody drug conjugate of any one of claims 288 to 359, wherein the antibody comprises a V_H-sequence of SEQ ID NO:769 and a V_L-sequence of SEQ ID NO:770.~~

~~400.—The antibody drug conjugate of any one of claims 288 to 399, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~401. The antibody drug conjugate of claim 400, wherein the antibody comprises: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~402. The antibody drug conjugate of claim 400, wherein the antibody comprises: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~403. The antibody drug conjugate of any one of claims 288 to 402, wherein the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~404. The antibody drug conjugate of claim 403, wherein the antibody consists of: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~405. The antibody drug conjugate of claim 403, wherein the antibody consists of: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~406. The antibody drug conjugate of any one of claims 288 to 405, wherein the presence of FVIIa does not interfere with the activity of the antibody drug conjugate compared to the absence of FVIIa.~~

~~407. The antibody drug conjugate of any one of claims 288 to 406, wherein the presence of FVIIa maintains the activity of the antibody drug conjugate compared to the absence of FVIIa.~~

~~408. An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the~~

~~antibody to the cytotoxic agent, wherein the antibody competes for binding to human TF with: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.~~

~~409.—The antibody drug conjugate of claim 408, wherein the antibody inhibits FVIIa-dependent TF signaling.~~

~~410.—The antibody drug conjugate of claim 408 or 409, wherein the antibody binds to cynomolgus TF.~~

~~411.—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~412.—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~413.—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~414.—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid~~

~~residues 77-85 and 92-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~**415.**—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-93 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-98 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.~~

~~**416.**—The antibody drug conjugate of claim 408 or 410, wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; and~~

~~wherein the binding between the antibody and a human TF extracellular domain with amino acid residues 78-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 77-85 and 92-112 of the sequence shown in SEQ ID~~

NO:838 is greater than 50% of the binding between the antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,

as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

~~417.~~—The antibody drug conjugate of any one of claims 408 to 416, wherein the antibody comprises all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E.

~~418.~~—The antibody drug conjugate of claim 417, wherein the three heavy chain CDRs and the three light chain CDRs are determined using Kabat, Chothia, AbM, Contact, or IMGT numbering.

~~419.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1F.

~~420.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1G.

~~421.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29D.

~~422.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29E.

~~423.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 39A.

~~424.~~—The antibody drug conjugate of claim 417 or 418, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 54E.

~~425.~~—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:37 and a V_L sequence of SEQ ID NO:38.

~~426.~~—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:75 and a V_L sequence of SEQ ID NO:76.

~~427.~~—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:341 and a V_L sequence of SEQ ID NO:342.

~~428. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:379 and a V_L sequence of SEQ ID NO:380.~~

~~429. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:417 and a V_L sequence of SEQ ID NO:418.~~

~~430. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H sequence of SEQ ID NO:759 and a V_L sequence of SEQ ID NO:760.~~

~~431. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises: a V_H CDR1 comprising the sequence set forth in SEQ ID NO:773; a V_H CDR2 comprising the sequence set forth in SEQ ID NO:774; a V_H CDR3 comprising the sequence set forth in SEQ ID NO:775; a V_L CDR1 comprising the sequence set forth in SEQ ID NO:776; a V_L CDR2 comprising the sequence set forth in SEQ ID NO:777; and a V_L CDR3 comprising the sequence set forth in SEQ ID NO:778.~~

~~432. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises: a V_H CDR1 comprising the sequence set forth in SEQ ID NO:785; a V_H CDR2 comprising the sequence set forth in SEQ ID NO:786; a V_H CDR3 comprising the sequence set forth in SEQ ID NO:787; a V_L CDR1 comprising the sequence set forth in SEQ ID NO:788; a V_L CDR2 comprising the sequence set forth in SEQ ID NO:789; and a V_L CDR3 comprising the sequence set forth in SEQ ID NO:790.~~

~~433. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises: a V_H CDR1 comprising the sequence set forth in SEQ ID NO:791; a V_H CDR2 comprising the sequence set forth in SEQ ID NO:792; a V_H CDR3 comprising the sequence set forth in SEQ ID NO:793; a V_L CDR1 comprising the sequence set forth in SEQ ID NO:794; a V_L CDR2 comprising the sequence set forth in SEQ ID NO:795; and a V_L CDR3 comprising the sequence set forth in SEQ ID NO:796.~~

~~434. The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises: a V_H CDR1 comprising the sequence set forth in SEQ ID NO:803; a V_H CDR2 comprising the sequence set forth in SEQ ID NO:804; a V_H CDR3 comprising the sequence set forth in SEQ ID NO:805; a V_L CDR1 comprising the sequence set forth in SEQ ID NO:806; a V_L CDR2 comprising the sequence set forth in SEQ ID NO:807; and a V_L CDR3 comprising the sequence set forth in SEQ ID NO:808.~~

~~435.—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H-sequence of SEQ ID NO:761 and a V_L-sequence of SEQ ID NO:762.~~

~~436.—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H-sequence of SEQ ID NO:765 and a V_L-sequence of SEQ ID NO:766.~~

~~437.—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H-sequence of SEQ ID NO:767 and a V_L-sequence of SEQ ID NO:768.~~

~~438.—The antibody drug conjugate of any one of claims 408 to 418, wherein the antibody comprises a V_H-sequence of SEQ ID NO:771 and a V_L-sequence of SEQ ID NO:772.~~

~~439.—The antibody drug conjugate of any one of claims 408 to 438, wherein the antibody comprises: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.~~

~~440.—The antibody drug conjugate of any one of claims 408 to 439, wherein the antibody consists of: the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.~~

~~441.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF)-antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:773; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:774; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:775; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:776; a V_L-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a V_L-CDR3 comprising the sequence set forth in SEQ ID NO:778.~~

~~442.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF)-antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a V_H-CDR1 comprising the sequence set forth in SEQ ID NO:779; a V_H-CDR2 comprising the sequence set forth in SEQ ID NO:780; a V_H-CDR3 comprising the sequence set forth in SEQ ID NO:781; a V_L-CDR1 comprising the sequence set forth in SEQ ID NO:782; a V_L-CDR2 comprising the sequence~~

set forth in SEQ ID NO:783; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:784.

~~443.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:790.~~

~~444.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:796.~~

~~445.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:802.~~

~~446.—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL CDR2 comprising the sequence~~

set forth in SEQ ID NO:807; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:808.

~~447.~~—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:877.

~~448.~~—An antibody drug conjugate comprising: an anti-human Tissue Factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody comprises: a VH CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL CDR3 comprising the sequence set forth in SEQ ID NO:883.

~~449.~~—The antibody drug conjugate of any one of claims 288 to 448, wherein the antibody is human, humanized, or chimeric.

~~450.~~—The antibody drug conjugate of any one of claims 288 to 449, wherein the antibody binds to human TF with a K_D of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM or 0.1 nM, as measured by Octet QK384 or Biacore assay.

~~451.~~—The antibody drug conjugate of any one of claims 288 to 449, wherein the antibody is a monoclonal antibody.

~~452.~~—The antibody drug conjugate of any one of claims 288 to 451, wherein the antibody is multispecific.

~~453.~~—The antibody drug conjugate of any one of claims 288 to 452, wherein the antibody is a Fab, Fab', F(ab')₂, Fv, scFv, (scFv)₂, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody.

~~454.—The antibody drug conjugate of any one of claims 288 to 453, wherein the antibody comprises a scaffold, optionally wherein the scaffold is Fe, optionally human Fe.~~

~~455.—The antibody drug conjugate of claim 454, wherein the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.~~

~~456.—The antibody drug conjugate of claim 455, wherein the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.~~

~~457.—The antibody drug conjugate of claim 456, wherein the antibody comprises a heavy chain constant region of IgG1.~~

~~458.—The antibody drug conjugate of any one of claims 454 to 457, wherein the Fe comprises one or more modifications, wherein the one or more modifications result in increased half life, increased antibody dependent cellular cytotoxicity (ADCC), increased antibody dependent cellular phagocytosis (ADCP), increased complement dependent cytotoxicity (CDC), or decreased effector function, compared with the Fe without the one or more modifications.~~

~~459.—An antibody drug conjugate comprising: an anti human Tissue Factor (anti hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody competes for binding to human TF with the antibody of any one of claims 288 to 458.~~

~~460.—An antibody drug conjugate comprising: an anti human Tissue Factor (anti hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker that links the antibody to the cytotoxic agent, wherein the antibody binds the human TF epitope bound by the antibody of any one of claims 288 to 459.~~

~~461.—The antibody drug conjugate of any one of claims 288 to 460, wherein the cytotoxic agent comprises an anti angiogenic agent, a pro apoptotic agent, an anti mitotic agent, an anti kinase agent, an alkylating agent, a hormone, a hormone agonist, a hormone antagonist, a chemokine, a drug, a prodrug, a toxin, an enzyme, an antimetabolite, an antibiotic, an alkaloid, or a radioactive isotope.~~

~~462.—The antibody drug conjugate of any one of claims 288 to 461, wherein the cytotoxic agent comprises at least one of: calicheamycin, camptothecin, carboplatin, irinotecan, SN-38, carboplatin, camptothecin, cyclophosphamide, cytarabine, dacarbazine, docetaxel,~~

~~dactinomycin, daunorubicin, doxorubicin, doxorubicin, etoposide, idarubicin, topotecan, vinca alkaloid, maytansinoid, maytansinoid analog, pyrrolobenzodiazepine, taxoid, duocarmycin, dolastatin, and auristatin.~~

~~463.—The antibody drug conjugate of any one of claims 288 to 462, wherein the linker comprises a labile linker, an acid labile linker, a photolabile linker, a charged linker, a disulfide-containing linker, a peptidase-sensitive linker, a β -glucuronide linker, a dimethyl-linker, a thio-ether linker, or a hydrophilic linker.~~

~~464.—The antibody drug conjugate of any one of claims 288 to 463, wherein the linker is a cleavable linker.~~

~~465.—The antibody drug conjugate of any one of claims 288 to 463, wherein the linker is a non-cleavable linker.~~

~~466.—A pharmaceutical composition comprising the antibody drug conjugate of any one of claims 288 to 465 and a pharmaceutically acceptable excipient.~~

~~467.—A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of the antibody drug conjugate of any one of claims 288 to 465 or the pharmaceutical composition of claim 466.~~

~~468.—The method of claim 467, wherein the disease or condition is cancer.~~

~~469.—The method of claim 468, wherein the cancer is head and neck cancer.~~

~~470.—The method of claim 468, wherein the cancer is ovarian cancer.~~

~~471.—The method of claim 468, wherein the cancer is gastric cancer.~~

~~472.—The method of claim 468, wherein the cancer is esophageal cancer.~~

~~473.—The method of claim 468, wherein the cancer is cervical cancer.~~

~~474.—The method of claim 468, wherein the cancer is prostate cancer.~~

~~475.—The method of claim 468, wherein the cancer is pancreatic cancer.~~

~~476.—The method of claim 468, wherein the cancer is estrogen receptors negative (ER-), progesterone receptors negative (PR-), and HER2 negative (HER2-) triple negative breast cancer.~~

~~477.—The method of claim 468, wherein the cancer is glioblastoma.~~

- ~~478.~~—The method of claim 468, wherein the cancer is lung cancer.
- ~~479.~~—The method of claim 468, wherein the cancer is bladder cancer.
- ~~480.~~—The method of claim 468, wherein the cancer is melanoma.
- ~~481.~~—The method of claim 468, wherein the cancer is kidney cancer.
- ~~482.~~—The method of any one of claims 467 to 481, further comprising administering one or more additional therapeutic agents to the subject.
- ~~483.~~—The method of claim 482, wherein the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody drug conjugate.
- ~~484.~~—The method of claim 482, wherein the additional therapeutic agent is formulated in a different pharmaceutical composition from the antibody drug conjugate.
- ~~485.~~—The method of claim 482, wherein the additional therapeutic agent is administered prior to administering the antibody drug conjugate.
- ~~486.~~—The method of claim 482, wherein the additional therapeutic agent is administered after administering the antibody drug conjugate.
- ~~487.~~—The method of claim 482, wherein the additional therapeutic agent is administered contemporaneously with the antibody drug conjugate.
- ~~488.~~—A method of detecting TF in a subject having or suspected of having a disease or condition, the method comprising: (a) administering to the subject the antibody drug conjugate of any one of claims 288 to 465; and (b) detecting the presence or the level of TF in the subject.
- ~~489.~~—The method of claim 488, wherein the disease or condition is cancer.
- ~~490.~~—The method of claim 489, wherein the cancer is head and neck cancer.
- ~~491.~~—The method of claim 489, wherein the cancer is ovarian cancer.
- ~~492.~~—The method of claim 489, wherein the cancer is gastric cancer.
- ~~493.~~—The method of claim 489, wherein the cancer is esophageal cancer.
- ~~494.~~—The method of claim 489, wherein the cancer is cervical cancer.
- ~~495.~~—The method of claim 489, wherein the cancer is prostate cancer.
- ~~496.~~—The method of claim 489, wherein the cancer is pancreatic cancer.

~~497. The method of claim 489, wherein the cancer is estrogen receptors negative (ER -), progesterone receptors negative (PR -), and HER2 negative (HER2 -) triple negative breast cancer.~~

~~498. The method of claim 489, wherein the cancer is glioblastoma.~~

~~499. The method of claim 489, wherein the cancer is lung cancer.~~

~~500. The method of claim 489, wherein the cancer is bladder cancer.~~

~~501. The method of claim 489, wherein the cancer is melanoma.~~

~~502. The method of claim 489, wherein the cancer is kidney cancer.~~

~~503. A kit comprising the antibody drug conjugate of any one of claims 288 to 465 or the pharmaceutical composition of claim 466 and instructions for use.~~

CLAIMS

1. An isolated antibody which binds to human Tissue Factor (TF), wherein the isolated antibody comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain complementarity determining regions (CDRs) (VL-CDR1, VL-CDR2, and VL-CDR3), wherein the VH-CDR1, VH-CDR2, and VH-CDR3 are from a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO:836, and wherein the VL-CDR1, VL-CDR2, and VL-CDR3 are from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO:837.

2. An isolated antibody which binds to human TF and comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain CDRs (VL-CDR1, VL-CDR2, and VL-CDR3), wherein : the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 890, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 891, and the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 892, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 893, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 894, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:895, and wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are defined according to the Kabat numbering system.

3. The isolated antibody of claim 1, wherein

(i) the isolated antibody binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa the isolated antibody binds to the extracellular domain; and

(ii) the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO:810 is greater than

50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 1-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 1-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 39-77 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 38-76 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 94-107 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 99-112 of the sequence shown in SEQ ID NO:838 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810;

the binding between the isolated antibody and a human TF extracellular domain with amino acid residues 146-158 of the sequence shown in SEQ ID NO:810 replaced by rat TF extracellular domain amino acid residues 151-163 of the sequence shown in SEQ ID NO:838 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810; or

the binding between the isolated antibody and a rat TF extracellular domain with amino acid residues 141-194 of the sequence shown in SEQ ID NO:838 replaced by human TF extracellular domain amino acid residues 136-189 of the sequence shown in SEQ ID NO:810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810,

as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.

4. The isolated antibody of claim 1, wherein the antibody:

(i) binds to cynomolgus TF;

(ii) binds to rabbit TF; and

(iii) binds to pig TF.

5. The isolated antibody of claim 1, wherein the antibody:

(a) does not inhibit human thrombin generation as determined by thrombin generation assay (TGA);

(b) allows human thrombin generation as determined by thrombin generation assay (TGA);

(c) binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX;

(d) does not interfere with the ability of TF:FVIIa to convert FX into FXa;

(e) does not compete for binding to human TF with FVIIa; and

(f) inhibits FVIIa-dependent TF signaling.

6. The isolated antibody of claim 1, wherein the antibody:

(a) does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;

(b) does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control;

(c) does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control;

(d) maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control;

(e) maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control; and

(f) preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control.

7. The isolated antibody of claim 1, wherein the antibody reduces lesion size in a swine choroidal neovascularization (CNV) model.

8. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 50 nM, as measured by Octet QK384 or Biacore assay.

9. The isolated antibody of claim 1, wherein the antibody is human, humanized, or chimeric.
10. The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody.
11. The isolated antibody of claim 1, wherein the antibody is multispecific.
12. The isolated antibody of claim 1, wherein the antibody is a Fab, Fab', F(ab')₂, Fv, scFv, (scFv)₂, single chain antibody molecule, dual variable domain antibody, linear antibody, or V domain antibody.
13. The isolated antibody of claim 1, wherein the antibody comprises an Fc region.
14. The isolated antibody of claim 1, wherein:
- (i) the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, or
- (ii) the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
15. The isolated antibody of claim 2, wherein:
- (i) the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, or
- (ii) the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
16. The isolated antibody of claim 1, wherein the antibody comprises a heavy chain constant region of human IgG1.
17. The isolated antibody of claim 2, wherein the antibody comprises a heavy chain constant region of human IgG1.
18. A pharmaceutical composition comprising (i) the isolated antibody of claim 1 and (ii) a pharmaceutically acceptable excipient.
19. A kit comprising the isolated antibody of claim 1 and instructions for use.
20. The isolated antibody of claim 1, wherein the sequence of the VH comprises the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:837.

21. The isolated antibody of claim 1, wherein the sequence of the VH consists of the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL consists of the amino acid sequence set forth in SEQ ID NO:837.
22. The isolated antibody of claim 20, wherein the antibody comprises a heavy chain constant region of human IgG1.
23. The isolated antibody of claim 21, wherein the antibody comprises a heavy chain constant region of human IgG1.
24. A pharmaceutical composition comprising (i) the isolated antibody of claim 20 and (ii) a pharmaceutically acceptable excipient.
25. A pharmaceutical composition comprising (i) the isolated antibody of claim 21 and (ii) a pharmaceutically acceptable excipient.
26. A pharmaceutical composition comprising (i) the isolated antibody of claim 22 and (ii) a pharmaceutically acceptable excipient.
27. A pharmaceutical composition comprising (i) the isolated antibody of claim 23 and (ii) a pharmaceutically acceptable excipient.
28. The isolated antibody of claim 2, wherein the sequence of the VH comprises the amino acid sequence set forth in SEQ ID NO:836, and the sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:837.
29. The isolated antibody of claim 2, wherein the sequence of the VH consists of the amino acid sequence set forth in SEQ ID NO:836 and the sequence of the VL consists of the amino acid sequence set forth in SEQ ID NO:837.
30. The isolated antibody of claim 28, wherein the antibody comprises a heavy chain constant region of human IgG1.
31. The isolated antibody of claim 29, wherein the antibody comprises a heavy chain constant region of human IgG1.
32. A pharmaceutical composition comprising (i) the isolated antibody of claim 28 and (ii) a pharmaceutically acceptable excipient.
33. A pharmaceutical composition comprising (i) the isolated antibody of claim 29 and (ii) a pharmaceutically acceptable excipient.

34. A pharmaceutical composition comprising (i) the isolated antibody of claim 30 and (ii) a pharmaceutically acceptable excipient.
35. A pharmaceutical composition comprising (i) the isolated antibody of claim 31 and (ii) a pharmaceutically acceptable excipient.
36. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 10 nM, as measured by Octet QK384 or Biacore assay.
37. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 5 nM, as measured by Octet QK384 or Biacore assay.
38. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 1 nM, as measured by Octet QK384 or Biacore assay.
39. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 0.5 nM, as measured by Octet QK384 or Biacore assay.
40. The isolated antibody of claim 1, wherein the antibody binds to human TF with a K_D of less than or equal to 0.1 nM, as measured by Octet QK384 or Biacore assay.